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INTRODUCTION
The AMPLATZER™ septal occluder, AMPLATZER™ muscular ventricular septal defect (VSD) occluder, and AMPLATZER™ duct occluder devices are used extensively for closure of septal defects in congenital heart disease and more recently for nonconventional and off-label uses. [1] [2] [3] [4] [5] The AMPLATZER™ muscular VSD occluder has been used for patent ductus arteriosus occlusion, [6] perforated sinus of Valsalva aneurysm closure, [7] and closure of pulmonary artery (PA) to left atrium fistulae. [8, 9] There are two case reports of muscular VSD occluders used for closure of native right ventricular outflow tract (RVOT), one in a patient with bidirectional cavopulmonary anastomosis and the other in a patient with repaired tetralogy of Fallot (TOF) with limited follow-up. [10, 11] We report the case of a 38-year-old male with TOF, status-post repair with a right ventricle (RV) to PA homograft due to an abnormal coronary artery pattern. He recently underwent Melody ® valve placement for conduit insufficiency, but remained symptomatic due to a persistently dilated RV and a significantly regurgitant native RVOT. He had a successful percutaneous closure of the native RVOT using an AMPLATZER™ muscular VSD occluder with persistent closure at the 5-year follow-up.
CASE REPORT
Our patient is a 38-year-old male born with TOF, right aortic arch with mirror image branching, left superior vena cava draining to the coronary sinus, and a large accessory left anterior descending coronary artery change in the RVSP. The patient was hemodynamically stable. There was no ST segment or T-wave changes noted on the continuously monitored electrocardiography. However, specific coronary angiographies were not performed before the device placement. The narrowest diameter of the native RVOT was 13-15 mm at its mid-portion. An 18-mm AMPLATZER™ muscular VSD occluder was delivered with the center waist at the narrowest portion of the RVOT. The device remained in satisfactory position after release [ Figure 2 ]. After device closure, there was no significant change in the RVSP (52% systemic). There were no complications.
The patient tolerated the procedure well and was discharged home the next day on aspirin. On follow-up 3 years after the device placement, there was no regurgitation of the native pulmonary tract and the RVSP was stable (40 mmHg). A computed tomography scan showed satisfactory position of the device [ Figure 3 ]. However, at 5-year follow-up, echocardiography showed increased RV pressure at 76 mmHg due to type II fractures of the Melody ® valve with loss of stent integrity. At this time, the homograft was replaced using a 25-mm porcine-valved conduit.
DISCUSSION
Percutaneous devices are utilized increasingly for imaginative off-label use to decrease the number of surgical interventions in patients with unrepaired or repaired congenital heart defects. TOF survivors with the need for RV-to-PA homograft often require multiple surgical revisions due to outgrowing the size of the homograft or due to conduit valve dysfunction. In patients who require the initial repair with a conduit due to an abnormal coronary artery pattern, the native pulmonary outflow tract is often left open to allow for a second pathway for blood to exit the RV, in the event of conduit originating from the right coronary artery and crossing the RVOT to the ventricular septum. He initially underwent placement of a left Blalock-Taussig shunt in infancy followed by a complete repair at 6 months of age with the placement of a RV to PA homograft due to the coronary artery abnormality. His homograft was subsequently repaired at 13 years of age, with the removal of the valve and placement of a patch over the anterior surface of the homograft. Over the years, he developed worsening homograft stenosis and regurgitation. Cardiac magnetic resonance imaging showed mild RV dilation with an end-diastolic volume index of 139.2 ml/m 2 , RV end-systolic volume index of 70.6 ml/m 2 , and RV ejection fraction of 49.3%. There was dual outflow from the RV to the PAs via the homograft and the native RVOT, and the combined regurgitant fraction was 63%. He developed nonsustained ventricular tachycardia (VT) thought secondary to increased right ventricular systolic pressure (RVSP) and volume overload. At 31 years of age, he underwent Implantable Cardioverter-Defibrillator (ICD) placement for the VT as well as placement of a Melody ® valve for the homograft stenosis and insufficiency. Prestenting was not performed due to the relatively mild degree of stenosis. The native outflow tract remained open and continued to be a source of moderate-to-severe regurgitation. He continued to complain of significant fatigue and inability to keep up with activities of daily living despite successful elimination of the homograft insufficiency by Melody ® valve placement. Transthoracic echocardiography showed the RV to be moderately dilated with mild stenosis at the Melody ® valve. Doppler interrogation of the native RVOT revealed moderate-to-severe insufficiency [ Figure 1 ]. Due to the symptoms, persistent RV dilation, and severe regurgitation from the native RVOT, we decided to close the native RVOT by percutaneous intervention.
Cardiac catheterization was performed under general anesthesia. RVSP was moderately elevated (49% systemic), and there was a 10 mmHg peak gradient across the Melody ® valve. The pulmonary capillary wedge pressure was mildly elevated (16 mmHg). There was free pulmonary insufficiency through the native RVOT [ Figure 2] . A 24-mm AMPLATZER™ Sizing Balloon was used for test occlusion of the native RVOT, with no stenosis. [12] The major drawback of leaving the native RVOT is development of progressive regurgitation leading to RV dilatation and associated symptoms. [13] When a patient develops symptoms or significant RV dilatation due to native RVOT insufficiency, the native tract can be closed surgically or by transcatheter device placement.
The AMPLATZER™ muscular VSD occluder has been described twice in the past to close the native RVOT. The first case was in a 12-month-old child with bidirectional cavopulmonary anastomosis to prevent excessive antegrade pulmonary blood flow.
[10] The second case report was in a 13-year-old patient, similar to our case, with TOF and a conduit repair. The patient had a limited follow-up of only 18 months after closure of the native RVOT with no complications. [11] In our patient, surgical closure of the native RVOT would have entailed dissection near the aberrant coronary artery as well as the removal of the competent Melody ® valve, which was not clinically necessary. Percutaneous closure of the native RVOT allowed a less invasive, nonsurgical procedure that spared the Melody ® valve and alleviated his symptoms of pulmonary insufficiency. The patient has since undergone homograft replacement 5 years after RVOT device closure, giving him those 5 additional years without a need for surgical intervention and a persistently occluded native RVOT for the future. At the recent conduit replacement surgery, the native RVOT device was found to be in satisfactory position and working well; thus, it was left untouched [ Figure 4 ].
CONCLUSION
We believe that the cause of his symptoms was a combination of the regurgitation from the native RVOT as well as the conduit. He had improvement in his symptoms post-RVOT occlusion and a conduit change was deferred for 5 years.
Our case is unique due to the patient's adult age, longer follow-up, and direct visualization of the device by the surgeon at conduit revision. The anatomic similarity of the stenosed native RVOT to the congenital muscular VSD (for which this device was initially intended) makes the AMPLATZER™ muscular VSD occluder an attractive choice for these kinds of procedures. Longer follow-up is necessary in all patients in whom devices are used in nonconventional ways.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest. 
